Bio-Techne (TECH)

Health Care · $11.4B market cap · SEC CIK 0000842023

Next reports on Feb 2, 2027, with analysts expecting $0.49 in earnings per share.

52-week range $43.20 to $72.88. At its 52-week high and 69% above its low.

The case for TECH

• Generated $263M of free cash flow in FY2026, 22% of revenue.
• Holds more cash ($265M) than long-term debt ($200M).
• Earnings per share up 158.9%.
• Gross margin of 66% absorbs cost shocks.
• Current assets cover the near-term bills 4.5 times over.
• Within 1% of its 52-week high: the trend is up.

The case against

• Expensive for its growth: 62.9× earnings, where 4% a year of growth would justify about 14×.
• Priced at 9.4× sales with revenue falling 0.4%.
• Revenue was flat on the year (−0.4%).

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Bio-Techne's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Bio-Techne says it does

OVERVIEW Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (“Bio-Techne”, “we”, “our”, “us” or the “Company”), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This…

Risk factors TECH lists in its 10-K

• Set forth below are risks and uncertainties we believe are material to our investors. You should refer to the explanation of the qualifications and limitations on forward-looking statements in the section titled
• at the beginning of this Annual Report on Form 10-K
• Conditions in the global economy, the particular markets we serve and the financial markets, whether brought about by material global crises or other factors, may adversely affect our business and financial results
• International political, compliance and business factors, including the military conflicts and trade tensions, can negatively impact our operations and financial results
• Our inability to complete acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price
• Our acquisition of businesses, investments, joint ventures and other strategic relationships, if not properly implemented or integrated, could negatively impact our business and financial results
• We may be required to record a significant charge to earnings if our goodwill and other amortizable intangible assets or other investments become impaired, which could negatively impact our financial results or stock price
• Our success will be dependent on recruiting and retaining highly qualified and diverse personnel and creating and maintaining a culture that successfully integrates the employees joining through acquisitions
• Our growth depends in part on the timely development and commercialization of new and enhanced products and services that meet our customers
• needs. Our growth can also be negatively impacted if our customers do not grow as anticipated
• We face intense competition, and if we are unable to compete effectively, we may experience decreased demand and decreased market share or need to reduce prices to remain competitive
• If we suffer loss to our supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed
• Climate change and/or related environmental risks, or legal or regulatory measures to address climate change and/or related environmental risks, may negatively affect us
• Defects, unanticipated use of, or inadequate disclosure with respect to our products, or allegations thereof, can adversely affect our business and financial results
• The proposed acquisition of the Company by Merck KGaA, Darmstadt, Germany may disrupt or adversely affect our business, prospects, financial condition and results of operations
• We have incurred and expect to continue to incur substantial transaction-related fees and costs in connection with the Merger
• The Merger may not be completed within the expected timeframe, or at all, and a significant delay in or the failure to complete the Merger could adversely affect our business and the market price of our common stock
• The Merger Agreement contains provisions that could discourage a potential competing acquirer of the Company or could result in a competing proposal being made at a lower price than it otherwise might have been
• Our business and financial results can be adversely affected by foreign currency exchange rates, changes in our tax rates and tax liabilities and assessments (including as a result of changes in tax laws)
• Dividends on our common stock could be reduced or eliminated in the future
• Our business is subject to extensive regulation; failure to comply with these regulations could adversely affect our business and financial results
• Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, can have an adverse effect on our business and financial results
• Our business and financial results can be impaired by improper conduct by any of our employees, agents or business partners
• Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to the Company
• s reputation and have a material adverse effect upon the Company
• s business, a risk that has been elevated with recent acquisitions that use protected health information and utilize healthcare providers for laboratory testing services

Filings

Other Health Care companies